About Tobira Development (NASDAQ:TBRA)
Tobira Therapeutics, Inc. is a United States-based clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of therapies for non-alcoholic steatohepatitis (NASH) and other liver diseases. The Company's product candidate, cenicriviroc (CVC), is a first-in-class immunomodulator and dual inhibitor of C-C chemokine receptor type 2 (CCR2) and C-C chemokine receptor type 5 (CCR5) in late stage development for the treatment of NASH, a serious liver disease that can progress to cirrhosis, liver cancer and liver failure. CVC is also being investigated to address primary sclerosing cholangitis (PSC), a disease which causes inflammation and scarring of the bile ducts, eventually leading to liver damage. The Company's pipeline also includes evogliptin, a selective dipeptidyl peptidase 4 (DPP-4) inhibitor, which it plans to develop for NASH in combination with CVC.
Industry, Sector and Symbol:
- 50 Day Moving Avg: $35.35
- 200 Day Moving Avg: $15.25
- 52 Week Range: $3.76 - $42.33
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -19.31
- P/E Growth: 0.00
- Return on Assets: -153.93%
- Debt-to-Equity Ratio: 0.44%
- Current Ratio: 5.38%
- Quick Ratio: 5.38%
- Average Volume: 583,983 shs.
- Beta: -2.38
Frequently Asked Questions for Tobira Development (NASDAQ:TBRA)
What is Tobira Development's stock symbol?
Tobira Development trades on the NASDAQ under the ticker symbol "TBRA."
How were Tobira Development's earnings last quarter?
Tobira Development Inc (NASDAQ:TBRA) announced its quarterly earnings results on Tuesday, August, 9th. The company reported ($0.71) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.63) by $0.08. The firm had revenue of $1.06 million for the quarter, compared to the consensus estimate of $0.15 million. View Tobira Development's Earnings History.
Where is Tobira Development's stock going? Where will Tobira Development's stock price be in 2017?
0 equities research analysts have issued 12 month target prices for Tobira Development's shares. Their forecasts range from $10,000,000.00 to $0.00. On average, they anticipate Tobira Development's stock price to reach $0.00 in the next year. View Analyst Ratings for Tobira Development.
Who are some of Tobira Development's key competitors?
Some companies that are related to Tobira Development include Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals Incorporated (VRTX), Kite Pharma (KITE), Exelixis (EXEL), Bioverativ (BIVV), bluebird bio (BLUE), TESARO (TSRO), Neurocrine Biosciences (NBIX), Juno Therapeutics (JUNO), Clovis Oncology (CLVS), BeiGene (BGNE), Sarepta Therapeutics (SRPT), Agios Pharmaceuticals (AGIO), AveXis (AVXS), GW Pharmaceuticals PLC (GWPH), Loxo Oncology (LOXO) and Spark Therapeutics (ONCE).
How do I buy Tobira Development stock?
Shares of Tobira Development can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Tobira Development's stock price today?
MarketBeat Community Rating for Tobira Development (NASDAQ TBRA)MarketBeat's community ratings are surveys of what our community members think about Tobira Development and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Tobira Development stock can currently be purchased for approximately $42.09.
Earnings History for Tobira Development (NASDAQ:TBRA)Earnings History by Quarter for Tobira Development (NASDAQ TBRA)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|8/9/2016||Q216||($0.63)||($0.71)||$0.15 million||$1.06 million||View||N/A|
Earnings Estimates for Tobira Development (NASDAQ:TBRA)
Current Year EPS Consensus Estimate: $-2.60 EPS
Next Year EPS Consensus Estimate: $-2.18 EPS
Dividend History for Tobira Development (NASDAQ:TBRA)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Tobira Development (NASDAQ:TBRA)
Insider Ownership Percentage: 6.20%Insider Trades by Quarter for Tobira Development (NASDAQ:TBRA)
Institutional Ownership Percentage: 62.42%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|10/31/2016||Pentwater Capital Management L||Major Shareholder||Buy||15,000||$41.84||$627,600.00|| |
|10/18/2016||Pentwater Capital Management L||Major Shareholder||Buy||40,000||$40.06||$1,602,400.00|| |
|10/17/2016||Pentwater Capital Management L||Major Shareholder||Buy||31,700||$40.07||$1,270,219.00|| |
|10/4/2016||Pentwater Capital Management L||Major Shareholder||Buy||4,481||$39.83||$178,478.23|| |
|9/29/2016||Pentwater Capital Management L||Major Shareholder||Buy||15,519||$39.49||$612,845.31|| |
|9/26/2016||Pentwater Capital Management L||Major Shareholder||Buy||50,000||$39.00||$1,950,000.00|| |
|9/23/2016||Pentwater Capital Management L||Major Shareholder||Buy||100,000||$39.19||$3,919,000.00|| |
|9/22/2016||Pentwater Capital Management L||Major Shareholder||Buy||1,624,200||$39.04||$63,408,768.00|| |
|7/13/2016||A/S Novo||Major Shareholder||Sell||59,067||$12.02||$709,985.34|| |
|7/7/2016||A/S Novo||Major Shareholder||Sell||92,119||$12.20||$1,123,851.80|| |
|6/30/2016||A/S Novo||Major Shareholder||Sell||66,814||$13.04||$871,254.56|| |
|6/6/2016||A/S Novo||Major Shareholder||Sell||187,500||$10.37||$1,944,375.00|| |
|3/4/2016||A/S Novo||Major Shareholder||Sell||190,000||$6.80||$1,292,000.00|| |
|11/18/2015||A/S Novo||major shareholder||Sell||225,000||$9.79||$2,202,750.00|| |
|5/4/2015||A/S Novo||Major Shareholder||Buy||838,041||$10.62||$8,899,995.42|| |
|5/4/2015||Parters Vii L P Domain||Major Shareholder||Buy||277,777||$10.62||$2,949,991.74|| |
|4/16/2014||Robert Kierlin||major shareholder||Buy||575,000||$6.00||$3,450,000.00|| |
|2/5/2014||Robert Kierlin||major shareholder||Buy||400,000||$5.00||$2,000,000.00|| |
|8/27/2013||Raphael Wisniewski||Director||Buy||1,215,708||$4.00||$4,862,832.00|| |
|8/27/2013||Rmi Investments S.A.R.L.||Major Shareholder||Buy||3,866,529||$4.00||$15,466,116.00|| |
Headline Trends for Tobira Development (NASDAQ:TBRA)
Latest Headlines for Tobira Development (NASDAQ:TBRA)
Loading headlines, please wait.
Tobira Development (TBRA) Chart for Monday, October, 23, 2017